Bilcare Ltd, India's leading pharmaceutical packaging research company, has acquired Pennsylvania-based ProClinical Inc, a privately held company offering formulation development of clinical supplies, analytical testing of materials, drug supply packaging and labelling.
 
ProClinical’s US FDA approved facility is spread across 14 acres of land and is Drug Enforcement Agency (DEA) licensed for controlled substances schedule I - V. With a team of 40 professionals, the pharmaceuticals services offered by ProClinical are Pre/formulation research & development, Analytical services including development, Clinical batch manufacturing & packaging, Distribution of clinical supplies including Interactive Voice Response System and Complete management of controlled drug substances.
 
While commenting on the acquisition from USA, Mohan Bhandari, chairman of Bilcare Ltd. said, "With its global facilities in Pune and Singapore, Bilcare has been continuously making efforts to broaden their participation in the pharma knowledge domain. Bilcare takes a significant leap in the pharma value chain, from drug discovery to market, through this US acquisition."
 
Bhandari further added, "The acquisition will significantly strengthen the company's position in the global pharma packaging research business and is a step towards attaining global leadership. ProClinical will enhance Bilcare's product& services range and the technical capabilities. Bilcare will be in a position to enlarge its product & service offerings for a potential value added packaging systems & services market."
 
ProClinical will help Bilcare strengthen and expand its business in USA through the addition of premium customer base such as J&J, Astra Zeneca, Bayer, Takeda, Merck etc., and more than 100 high growth biotech companies like Genzyme, Progenics among others.

The 160-crore pharma packaging company, Bilcare, with operations spread across India, is ISO 9002 and ISO 14001 accredited and has USFDA DMF assigned to its range of films and foils.